Lazy eyes listen
Moderna is hoping its mRNA technology will succeed where other HIV vaccines failed.
BY HANNAH SEO
Moderna announced last week that it has begun dosing its first participants in Phase I clinical trials for an HIV vaccine that uses the same mRNA technology as the company’s COVID-19 vaccine.
The company, which is conducting the trial in partnership with the nonprofit International AIDS Vaccine Initiative (IAVI), hopes the trial will confirm whether the vaccine can deliver HIV-specific antigens to the body and induce an immune response.
Researchers will study 56 HIV-negative adults for six months. Forty-eight of the volunteers will receive at least one dose of the primary vaccine, 32 of whom will also receive the booster. The remaining eight will receive the booster vaccine alone. The first participants were just vaccinated at George Washington University School of Medicine and Health Sciences in Washington, D.C.